Real-World HPV Vaccine Effectiveness Studies: Guideposts for Interpretation of Current and Future Studies

Menée au Danemark à partir de données 2006-2019 de registres portant sur 867 689 femmes âgées de 17 à 30 ans, cette étude estime l'efficacité de la vaccination anti-papillomavirus humain sur l'incidence du cancer du col de l'utérus, selon l'âge au moment du vaccin

Résumé en anglais

Registry-based effectiveness studies provide evidence for the real-world impact of the Human papillomavirus (HPV) vaccine. Given the length of time between acquisition of a “causal” HPV infection and cancer incidence, initial studies focused on the reduction of surrogate endpoints such as genital warts and cervical precancer. New, studies from Denmark and Sweden document the profound impact that HPV vaccination can have on reducing incidence of cervical cancer— a leading cause of cancer death in women, particularly in lowand middle-income countries.